Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fulvestrant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 10/20 | 0.76 |
| ▸ | ESRRA | P11474 | 9/20 | 0.76 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.76 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.76 |
| ▸ | PGR | P06401 | 1/20 | 0.76 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.76 |
| ▸ | PPARG | P37231 | 1/20 | 0.76 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.76 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.76 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.76 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | ESRRB | O95718 | 8/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fulvestrant SCHEMBL8427428 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| Fulvestrant SCHEMBL408338 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| Fulvestrant SCHEMBL14340043 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| Fulvestrant SCHEMBL22356606 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| Fulvestrant SCHEMBL23134939 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| Fulvestrant SCHEMBL20448785 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| Fulvestrant SCHEMBL23760281 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| SCHEMBL24511123 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| SCHEMBL23963146 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 | |
| Fulvestrant SCHEMBL22667548 | 1.00 | ESR1 (0.76) | ESR1ESRRAESR2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102458404-A | Treatment of hot flashes, vasomotor symptoms and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators | ENDORECH INC | 2012-05-16 | — | — | CN | claimed |
| US-20240092779-A1 | USP1 INHIBITORS AND USES THEREOF | ZENTAUR THERAPEUTICS USA INC. | 2024-03-21 | — | — | US | disclosed |
| US-11925651-B2 | TEAD inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-03-12 | — | — | US | disclosed |
| US-11918770-B2 | Implants for localized drug delivery and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-05 | — | — | US | disclosed |
| EP-4323066-A1 | MEK INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2024006879-A1 | USP1 INHIBITORS AND USES THEREOF | ZENTAUR THERAPEUTICS USA INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| EP-4255895-A1 | TEAD INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023192961-A2 | LIGAND-PAYLOAD CONJUGATES | PYXIS ONCOLOGY, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023173053-A1 | MEK INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023173057-A1 | MEK INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2023-09-14 | — | — | WO | disclosed |
| EP-2616078-A1 | FULVESTRANT COMPOSITIONS AND METHODS OF USE | Shimoda Biotech (Pty) Ltd (ZA) | 2013-07-24 | — | — | EP | disclosed |
| WO-2013033392-A1 | THERAPEUTIC COMPOUNDS AND METHODS | WAYNE STATE UNIVERSITY (US) | 2013-03-07 | — | — | WO | disclosed |
| EP-2536741-A2 | GENE FUSION TARGETED THERAPY | The Regents of The University of Michigan (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2012116317-A2 | COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS | MERRIMACK PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | WO | disclosed |
| WO-2012035516-A1 | FULVESTRANT COMPOSITIONS AND METHODS OF USE | SWART HENK (ZA) | 2012-03-22 | — | — | WO | disclosed |
| CN-102329270-A | Hydrosulfate | ARRAY BIOPHARMA INC | 2012-01-25 | — | — | CN | disclosed |
| CN-101360718-B | Bisulfate salt | ARRAY BIOPHARMA INC | 2012-01-11 | — | — | CN | disclosed |
| WO-2011103011-A2 | GENE FUSION TARGETED THERAPY | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011103016-A2 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-08-25 | — | — | WO | disclosed |
| CN-101360718-A | Novel bisulfate salt | ARRAY BIOPHARMA INC (US) | 2009-02-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11925651-B2 | TEAD inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | ESR1 1998/4885ESRRA 2250/4885ESR2 2374/4885 |
| US-20240092779-A1 | USP1 INHIBITORS AND USES THEREOF | USP1, USP28, USP2 | ESR1 2507/4885ESRRA 2057/4885ESR2 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.